Oncolytics Biotech has FDA alignment on a potential registrational path for pelareorep in RAS-mutant MSS metastatic colorectal cancer.
Potential pivotal Part B expansion of REO 033.
Potential accelerated approval pathway.
Now comes the data. ????
News: https://finance.yahoo.com/healthcare/articles...00976.html
Communicated Disclaimer: https://stockresearchtoday.com/oncy/